The challenge of risk prediction: How good are we?

Abstract

Get full access to this article

View all access options for this article.

References

Pavlovic

Greenland

Deckers

et al.

Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study. Eur J Prev Cardiol 2018; 25: 420–431.

Goff

Jr Lloyd-Jones

Bennett

et al.

2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935–2959.

Piepoli

Hoes

Agewall

et al.

2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315–2381.

Piepoli

Hoes

Agewall

et al.

Catapano

Graham

De Backer

et al.

2016 ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 253: 281–344.